Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
24/02/2026 13:02
Feb 24 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS DOSES FIRST PATIENT IN PHASE 1/2A CLINICAL STUDY OF BETABART (RV-01) Source text: ID:nGNX2dGvwX Further company coverage: RAD.AX (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%